Stay updated on Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial
Sign up to get notified when there's something new on the Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial page.

Latest updates to the Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial page
- Check3 days agoChange DetectedThis updates the ClinicalTrials.gov page’s display revision/version in the footer from v3.5.2 to v3.5.3, without changing any study details or record information.SummaryDifference0.0%

- Check10 days agoChange DetectedRevision label updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check39 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check46 days agoChange DetectedPage revision updated to v3.4.3 with new dates (2026-03-03, 2026-03-05, 2026-03) and the previous revision v3.4.2 removed.SummaryDifference0.2%

- Check75 days agoChange DetectedA new Revision: v3.4.2 tag appears and the prior government funding lapse notice is removed; the study details and page content remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check82 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and NIH Clinical Center status, and updated the page revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial page.